title: [External therapy of plasma cell mastitis by jiuyi powder using partial least-squares discriminant analysis: a safety analysis].
abstract: OBJECTIVE
  To evaluate the safety and the clinical value of external use of jiuyi Powder (JP) in treating plasma cell mastitis using partial least-squares discriminant analysis (PLSDA).
  
  
  METHODS
  Totally 50 patients with plasma cell mastitis treated by external use of JP were observed and biochemical examinations of blood and urine detected before application, at day 4 after application, at day 1 and 14 after discontinuation. Blood mercury and urinary mercury were detected before application, at day 1, 4, and 7 after application, at day 1 and 14 after discontinuation. Urinary mercury was also detected at 28 after discontinuation and 3 months after discontinuation. The information of wound, days of external application and the total dosage of external application were recorded before application, at day 1, 4, and 7 after application, as well as at day 1 after discontinuation. Then a discriminant model covering potential safety factors was set up by PLSDA after screening safety indices with important effects. The applicability of the model was assessed using area under ROC curve. Potential safety factors were assessed using variable importance in the projection (VIP).
  
  
  RESULTS
  Urinary β2-microglobulin (β2-MG), urinary N-acetyl-β-D-glucosaminidase (NAG), 24 h urinary protein, and urinary α1-microglobulin (α1-MG) were greatly affected by external use of JP in treating plasma cell mastitis. The accuracy rate of PLSDA discriminate model was 74. 00%. The sensitivity, specificity, and the area under ROC curve was 0. 7826, 0. 7037, and 0. 8084, respectively. Three factors with greater effect on the potential safety were screened as follows: pre-application volume of the sore cavity, days of external application, and the total dosage of external application.
  
  
  CONCLUSIONS
  PLSDA method could be used in analyzing bioinformation of clinical Chinese medicine. Urinary β2-MG and urinary NAG were two main safety monitoring indices. Days of external application and the total dosage of external application were main factors influencing blood mercury and urine mercury. A safety classification simulation model of treating plasma cell mastitis by external therapy of JP was established by the two factors, which could be used to assess the safety of external application of JP to some extent.
authors.forename: Mei-na
authors.initials: MN
authors.lastname: Ye
authors.forename: Ming
authors.initials: M
authors.lastname: Yang
authors.forename: Yi-qin
authors.initials: YQ
authors.lastname: Cheng
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhu
authors.forename: Ya-ru
authors.initials: YR
authors.lastname: Xia
authors.forename: Tian
authors.initials: T
authors.lastname: Meng
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.forename: Li-ying
authors.initials: LY
authors.lastname: Chen
authors.forename: Hong-feng
authors.initials: HF
authors.lastname: Cheng
mesh_terms: D000118:Acetylglucosaminidase; D000510:Alpha-Globulins; D016002:Discriminant Analysis; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016018:Least-Squares Analysis; D008413:Mastitis / Q000188:drug therapy*; D010950:Plasma Cells; D012372:ROC Curve; D012449:Safety
chemical_list: D000510:Alpha-Globulins; D004365:Drugs, Chinese Herbal; C016001:alpha-1-microglobulin; D000118:Acetylglucosaminidase